CELLULAR LONGEVITY, INC., DBA LOYAL
Loyal is a biotechnology company developing medicines to extend dog lifespan. By developing drugs with the potential to slow the aging process, they aim to delay or prevent age-related diseases like cancer and dementia.
CELLULAR LONGEVITY, INC., DBA LOYAL
Industry:
Biotechnology Pet Veterinary
Founded:
2019-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.loyalfordogs.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
58 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Kindred Biosciences
Kindred Biosciences is a veterinary biotechnology company that focuses on developing therapies for dogs, cats and horses.
Current Employees Featured
Founder
Investors List
Ashley Mayer
Ashley Mayer investment in Series A - Cellular Longevity, Inc., dba Loyal
Claire Hughes Johnson
Claire Hughes Johnson investment in Series A - Cellular Longevity, Inc., dba Loyal
BoxGroup
BoxGroup investment in Series A - Cellular Longevity, Inc., dba Loyal
Khosla Ventures
Khosla Ventures investment in Series A - Cellular Longevity, Inc., dba Loyal
First Round Capital
First Round Capital investment in Series A - Cellular Longevity, Inc., dba Loyal
LGF
LGF investment in Series A - Cellular Longevity, Inc., dba Loyal
Quiet Capital
Quiet Capital investment in Series A - Cellular Longevity, Inc., dba Loyal
Brianne Kimmel
Brianne Kimmel investment in Series A - Cellular Longevity, Inc., dba Loyal
The Longevity Fund
The Longevity Fund investment in Series A - Cellular Longevity, Inc., dba Loyal
Collaborative Fund
Collaborative Fund investment in Series A - Cellular Longevity, Inc., dba Loyal
Official Site Inspections
http://www.loyalfordogs.com Semrush global rank: 2.44 M Semrush visits lastest month: 7.34 K
- Host name: ec2-52-36-128-127.us-west-2.compute.amazonaws.com
- IP address: 52.36.128.127
- Location: Boardman United States
- Latitude: 45.8491
- Longitude: -119.7143
- Metro Code: 810
- Timezone: America/Los_Angeles
- Postal: 97818
More informations about "Cellular Longevity, Inc., dba Loyal"
About us - Loyal
Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs.See details»
Loyal - Crunchbase Company Profile & Funding
Contact Email [email protected] Loyal is a biotechnology company developing medicines to extend dog lifespan. By developing drugs with the …See details»
Loyal | Clinical trials
At Loyal, we’re a clinical-stage veterinary medicine company developing drugs intended to extend the healthy lifespan of dogs. We’ve launched the STAY study — a double-blinded, placebo …See details»
Cellular Longevity, Inc., dba Loyal - Email and contact information
Cellular Longevity, Inc., dba Loyal's email address is [email protected]. Where are Cellular Longevity, Inc., dba Loyal’s headquarters? Cellular Longevity, Inc., dba Loyal's headquarters …See details»
Loyal for Dogs - LifeScienceHistory.com
Loyalfordogs.com. 1841 Market St. Flr 3. San Francisco, CA 94013. Company Info Year Established 2019. Contacts Celine Halioua Founder & CEO Sudharika Gogna COO. Company …See details»
Loyal - LinkedIn
Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives.See details»
Cellular Longevity Inc (dba Loyal) - VentureRadar
Website: https://loyalfordogs.com. Develops and conducts research on clinical-stage animal health drugs designed to extend the lifespan and enhance the health of dogs by targeting the …See details»
Loyal Company Profile - Office Locations, Competitors, Revenue
Loyal $38 m in total funding,. See insights on Loyal including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Independent Board Member - Celine Halioua
Our end goal is a revenue-creating sustainable, venture scale organization that develops and commercializes aging drugs (AKA - not a build-to-buy play) We have a number of tailwinds: …See details»
Loyal For Dogs - YouTube
Loyal is a clinical-stage veterinary medicine company. We’re developing drugs intended to delay and reverse aging in dogs, because we believe they deserve as many happy years as we can …See details»
FDA Center for Veterinary Medicine agrees Loyal’s data supports ...
Nov 28, 2023 FDA Center for Veterinary Medicine agrees Loyal’s data supports reasonable expectation of effectiveness for large dog lifespan extensionSee details»
Biotech startup Loyal announces $45m Series B financing to …
Mar 25, 2024 Loyal, a biotech company pioneering longevity drugs for dogs, announced it has completed its Series B funding round, securing $45 million in investment.The round was led by …See details»
Morris Animal Foundation Partners with Loyal
DENVER/June 7, 2021 – In an effort to improve canine health and longevity, Morris Animal Foundation, a nonprofit leader in advancing animal health, is partnering with Loyal, a biotech …See details»
Loyal Reaches FDA Milestone for its Drug to Extend Healthy …
Nov 28, 2023 Loyal is a biotech startup developing the first drugs intended to help dogs live longer, healthier lives. By targeting the underlying mechani sms of aging, Loyal hopes to …See details»
The Future for Dogs Looks Longer and Healthier
Feb 20, 2024 A San Francisco biotech company called Loyal aims to extend the lifespan of dogs using three drugs: LOY-001, LOY-002, and LOY-003. These drugs reduce the IGF-1 hormone …See details»
Prelude and Loyal: Collaborating to Extend Canine Lifespans
AUSTIN, Texas, April 19, 2024 /PRNewswire/ -- Loyal, the San Francisco-based company dedicated to improving the health and longevity of dogs, and Prelude, the leading animal …See details»
Loyal’s latest milestone: the first longevity clinical study design ...
Mar 10, 2023 Some important news: Loyal has received protocol concurrence from the FDA on our companion dog longevity study. This means that the FDA has reviewed the scientific …See details»
Loyal Launches Nationwide, 1,000-Dog Clinical Trial for Drug to …
Feb 1, 2024 Tim Smith [email protected] 415-350-3019 Release Summary Biotech company Loyal launches nationwide, 1,000-dog clinical trial for its LOY-002 drug to extend …See details»
7 Most Faithful Dog Breeds That Never Let You Down
Mar 11, 2025 WorldAnimalFoundation.org is a leading digital platform advocating for animal rights, responsible pet ownership, and compassionate awareness. WAF is not a non-profit …See details»
Our LOY-002 clinical pilot study is now fully enrolled - Loyal Blog
Apr 11, 2023 We’ve now fully enrolled our first clinical study for LOY-002 — the internal name for our daily tablet intended to extend lifespan and quality of life for older dogs.See details»